# ICON Public Limited Company (ICLR)

> Source: Nexqual · https://nexqual.com/ICLR · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, ICON Public Limited Company (ICLR), nexqual.com/ICLR" · informational, not investment advice.

**Price:** USD 185.43 (+0.10% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 185.25 · day 181.81–190.56 · 52w 66.57–203.91 · market cap $14.3B · NMS

## Key facts
- Insider open-market sales, last ~7 months: 12 Form 4 filings, $4.0M; 12 not under a Rule 10b5-1 plan ($4.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.50 on a 1–5 scale) (18 analysts), mean target USD 188.24 (range 155–215).
- Total return with dividends: 1Y +3.0% vs S&P 500 +14.9%; 5Y -33.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 2.63, revenue estimate $2.01B.

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 12 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | McCague Eugene Pacelli | Director | 3,255 | $570K | 46.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-17 | Murphy Ronan Martin | Director | 5,005 | $876K | 56.5% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-09-16 | Climax John Dr | Director | 5,005 | $876K | 70.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Whitaker Anne Clem | Director | 841 | $138K | 48.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | O'Neill Julie | Director | 915 | $150K | 20.7% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Murray Ciaran | Director | 2,677 | $440K | 11.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Murphy Ronan Martin | Director | 841 | $138K | 17.9% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | McCague Eugene Pacelli | Director | 841 | $138K | 18.1% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Grais Linda | Director | 841 | $138K | 12% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Climax John Dr | Director | 841 | $138K | 28.7% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-11 | Clerkin Nigel Bernard John | Chief Financial Officer | 2,267 | $372K | 27.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-10 | Balfe Barry Edward | Chief Executive Officer | 382 | $63K | 7.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.50 on a 1–5 scale), 18 analysts; mean target USD 188.24 (low 155, high 215).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-18 | Citigroup | Target lowered | Neutral | $180 → $175 |
| 2026-07-31 | Citigroup | Target raised | Neutral | $165 → $180 |
| 2026-07-31 | Truist Securities | Target raised | Buy | $207 → $209 |
| 2026-06-30 | Truist Securities | Upgrade | Hold → Buy | $159 → $207 |
| 2026-06-26 | Mizuho | Target raised | Outperform | $180 → $190 |
| 2026-06-25 | Citigroup | Target raised | Neutral | $140 → $165 |
| 2026-06-25 | BMO Capital | Target raised | Outperform | $160 → $187 |
| 2026-06-25 | Barclays | Target raised | Equal-Weight | $160 → $175 |
| 2026-06-25 | RBC Capital | Upgrade | Sector Perform → Outperform | $126 → $185 |
| 2026-06-25 | TD Cowen | Target raised | Buy | $164 → $197 |
| 2026-06-25 | JP Morgan | Target raised | Neutral | $130 → $155 |
| 2026-06-25 | Evercore ISI Group | Target raised | Outperform | $150 → $180 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +3.0% | -33.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.0% | -7.7% |
| Volatility (annualized) | 73.6% | 48.0% |
| Max drawdown | -60.5% (Jan 2026→Feb 2026) | -72.3% (Jul 2024→Feb 2026) |

## Peers (Diagnostics & Research)
CRL (Charles River Laboratories Inte) USD 339.66 -1.51% · RVTY (Revvity, Inc.) USD 157.36 +0.48% · MEDP (Medpace Holdings, Inc.) USD 653.96 -1.29% · QGEN (Qiagen N.V.) USD 50.22 +0.44% · GH (Guardant Health, Inc.) USD 162.94 -2.23% · LH (Labcorp Holdings Inc.) USD 329.93 +1.91%

## More
Full page: https://nexqual.com/ICLR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in ICLR's own 20-F filed 2026-05-27 (https://www.sec.gov/Archives/edgar/data/1060955/000162828026038487/iclr-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | At ICON | "At ICON, the health and safety of our employees, customers and clinical trial patients are our most important priorities." |
| Partner | Accellacare | "The Accellacare Site Network encompasses 21 owned/embedded sites across the US, UK and Spain as well as a number of collaboration agreements with other sites." |
| Partner | ServiceNow (NOW) | "These include Veeva (SOP document management), Cornerstone (training delivery), ServiceNow (workflow and automation), SailPoint (identity governance), PEGA (safety reporting), Oracle ARGUS (pharmacovigilance), Salesforce…" |
| Partner | Oracle (ORCL) | "These include Veeva (SOP document management), Cornerstone (training delivery), ServiceNow (workflow and automation), SailPoint (identity governance), PEGA (safety reporting), Oracle ARGUS (pharmacovigilance), Salesforce…" |
| Partner | Salesforce (CRM) | "These include Veeva (SOP document management), Cornerstone (training delivery), ServiceNow (workflow and automation), SailPoint (identity governance), PEGA (safety reporting), Oracle ARGUS (pharmacovigilance), Salesforce…" |
| Partner | Microsoft (MSFT) | "These include Veeva (SOP document management), Cornerstone (training delivery), ServiceNow (workflow and automation), SailPoint (identity governance), PEGA (safety reporting), Oracle ARGUS (pharmacovigilance), Salesforce…" |

Other companies that name ICLR in their own reports (relationship from ICLR's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| supplier | Fortrea Holdings Inc. (FTRE) | 10-K 2026-02-26 | "The Peer Group consists of Charles River Laboratories Inc., ICON plc, Medpace Holdings, Inc., IQVIA Holdings Inc. and Thermo Fisher Scientific Inc. The companies in our Peer Group are publicly traded …" |
| supplier | IQVIA HOLDINGS INC. (IQV) | 10-K 2026-02-17 | "The peer group consists of Charles River Laboratories, Inc., Fortrea Holdings Inc., ICON plc, Medpace Holdings Inc., S&P Global Inc., Danaher Corporation and Thermo Fisher Scientific Inc. The companie…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $2.63 | $2.68 | -2.1% | $2.01B | 13 |
| Next quarter (ends 2026-12-31) | $2.85 | $2.86 | -0.4% | $2.02B | 14 |
| Current fiscal year (ends 2026-12-31) | $10.56 | $10.64 | -0.7% | $8.14B | 18 |
| Next fiscal year (ends 2027-12-31) | $11.77 | $11.87 | -0.8% | $8.41B | 18 |